Cargando…

Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720‐2A>G variant

BACKGROUND: The prognosis in polycythemia vera (PV) is comparatively favorable, but individual myelofibrosis/leukemic progression risk is heterogeneous. About a quarter of patients progress to the fibrotic phase after 20 years. METHODS: Multiplex PCR, allele‐specific qPCR, high‐resolution melt analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanduła, Zuzanna, Kroll‐Balcerzak, Renata, Lewandowski, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102755/ https://www.ncbi.nlm.nih.gov/pubmed/35435261 http://dx.doi.org/10.1002/jcla.24388

Ejemplares similares

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
por: Fei, Naomi, et al.
Publicado: (2017)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Progression of primary myelofibrosis to polycythemia vera: A case report
por: Guo, Yan, et al.
Publicado: (2017)

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
por: Kanduła, Zuzanna, et al.
Publicado: (2022)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis
por: Song, Jinming, et al.
Publicado: (2017)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Neuropsychiatric disturbance detecting polycythemia vera myelofibrosis: a case report and literature review
por: Li, Li, et al.
Publicado: (2023)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
por: Koshiishi, Megumi, et al.
Publicado: (2017)

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?
por: Silver, Richard T.
Publicado: (2020)

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)

Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations
por: Segura-Díaz, Adrián, et al.
Publicado: (2020)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis
por: Lighezan, Diana L., et al.
Publicado: (2020)

Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review
por: Hasui, Hidenari, et al.
Publicado: (2022)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Agarwal, M. B., et al.
Publicado: (2015)

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
por: Habberstad, Andreas Hanssønn, et al.
Publicado: (2018)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
por: Pimpinelli, Fulvia, et al.
Publicado: (2021)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors
por: Federici, Giulia, et al.
Publicado: (2019)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Chorea disclosing a polycythemia vera
por: Liu, Guidong, et al.
Publicado: (2014)

An oncolytic parasite to treat polycythemia vera
por: Rizvi, Syeda Taliya, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vnuq86isnjfnuin67lhl1uh6ao